What’s New
Whether you’re a client, a colleague, or simply interested in the current status of nonclinical drug development, we invite
you to explore and learn with us. Check back regularly for new content as we continue to add resources and updates.
What does it take to safely move a cell therapy from the lab to a patient? 🧬
Akkeri, Inc. is excited to announce Ewa Budzynski, PhD, DABT will be presenting on cell-based therapies and their path from bench to bedside at SOT 2026. The session...
Akkeri, Inc. proudly celebrates Diann Blanset, PhD, DABT for receiving the IQ Consortium 2025 Recognition Award in appreciation of her outstanding engagement and dedication to the DruSafe mission and goals. Diann served as the Co-Chair for the FDA Strategic..
Akkeri, Inc. is pleased to highlight not just one, but two sessions from our partner White Oak Regulatory Tox at SOT 2026!
Former FDA regulator Timothy McGovern, PhD will explore critical topics shaping regulatory science and pharmaceutical...